Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.

Nanobiotix has announced that it has secured c.€9 million in funding from bpifrance (formerly OSEO) of which €2.8 million is directly attributable to the Company.

This grant, awarded through bpifrance’s Strategic Industrial Innovation (ISI) program, will accelerate the clinical and industrial development of the Company’s lead product NBTXR3 in a new indication, liver cancer (hepatocellular carcinoma).

Liver cancer is a major health problem that causes one of the greatest number of deaths each year worldwide, c.695,000 deaths per annum.

This grant supports the launch of NICE (Nano Innovation for CancEr), the first consortium of nanomedicine stakeholders in France focused on characterization and industrialization aspects.

The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France (www.medicen.org).

Consisting of five public and private partners, the NICE consortium includes partners with in depth expertise in the field of nanomedicine.

Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for advanced soft tissue sarcoma and has received authorization from the French Medicine Agency, ANSM, to start a second clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer).

NBTXR3 will benefit fully from this platform of expertise and funding received from bpifrance by being able to accelerate its clinical development.

The purpose of this project is the start of a new Phase I clinical study with NBTXR3 in patients with primary liver cancer.

In addition to Nanobiotix, the consortium includes BioAlliance Pharma, leader of the consortium which is developing Livatag®, a doxorubicin nanoparticle currently in Phase III clinical trial for treatment of primary liver cancer; CEA-Leti, the developer of cancer-detecting nanoparticles based on Leti’s Lipidots® platform; DBI, a company specialized in the production of nanomedicine pharmaceutical products and the Institut Galien Paris Sud (University Paris Sud/CNRS), which has an academic-excellence team specialized in nanoparticle research.

“Today, nanomedicine is considered as one of the major growth drivers of the global pharmaceutical industry and it is essential that the industry is structured at the local level to be competitive,” said Laurent Levy, CEO of Nanobiotix.

Levy continued, “In turn, Nanobiotix will benefit from the consortium in two ways; if the sector is structured right to be able to accelerate the development and industrialization of products, and in the development of a new indication of NBTX3 which will help patients and build shareholder value.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
Scientific News
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!